Current Fungal Infection Reports

, Volume 6, Issue 4, pp 349–357

Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses

Hot Topic

DOI: 10.1007/s12281-012-0107-9

Cite this article as:
Lewis, R.E. & Viale, P. Curr Fungal Infect Rep (2012) 6: 349. doi:10.1007/s12281-012-0107-9

Abstract

Amphotericin B (AMB) has been used for nearly five decades in the treatment of life-threatening mycoses. While triazoles and echinocandins have largely supplanted the routine use of AMB for common Candida and Aspergillus infections, this prototypical broad-spectrum agent or its lipid formulations are still preferred by many clinicians as the initial empiric antifungal therapy for severely immunosuppressed patients, and remain the preferred treatment in combination with 5-fluorocytosine for cryptococcal meningioencephalitis. This article reviews progress over the last decade in understanding the pharmacology and clinical dosing of AMB formulations for common systemic mycoses, including invasive candidiasis, cryptococcosis, aspergillosis and mucormycosis.

Keywords

Amphotericin B Dosing Lipid amphotericin B Pharmacology Pharmacodynamics 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Medical and Surgical Sciences, Infectious Diseases Clinics, University of BolognaBolognaItaly